CeriBell (NASDAQ:CBLL) Announces Quarterly Earnings Results, Misses Expectations By $1.03 EPS

CeriBell (NASDAQ:CBLL) released its quarterly earnings results on Tuesday. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03), Zacks reports. The firm had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $17.06 million.

CeriBell Stock Down 1.2 %

Shares of NASDAQ:CBLL traded down $0.33 on Thursday, reaching $27.55. The company’s stock had a trading volume of 72,781 shares, compared to its average volume of 230,041. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.

Analyst Ratings Changes

Several equities analysts have recently commented on CBLL shares. Canaccord Genuity Group assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. began coverage on CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective for the company. TD Cowen initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $31.00 price target on the stock. William Blair began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. Finally, Canaccord Genuity Group lifted their price target on shares of CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Buy” and a consensus price target of $31.20.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.